 | |
|
Guidelines for the economic evaluation of pharmaceuticals
— can the UK learn from Australia and Canada? |
| Author(s) | Adrian Towse |
| Corporate Author | Office of Health Economics |
| Publisher | Office of Health Economics - OHE, London, 1997 |
| Pages | 70 pp |
| Source | Office of Health Economics, 12 Whitehall, London SW1A 2DY. |
| Keywords | Drugs ; Cost effectiveness ; National Health Service ; Management [care] ; Standards of provision ; Australasia ; Canada ; United Kingdom. |
| Annotation | This publication explores the impact in Australia, Canada and the UK of guidelines for the production of information on the cost-effectiveness of particular medicines. The role of the Association of the British Pharmaceutical Industry (ABPI) and the Prescriptions Medicines Code of Practice Authority established by the ABPI in 1993 is discussed. Information provided to the NHS on the economic value of a pharmaceutical should help decision makers achieve society's health care objective. However, use of such information to restrict access to treatment raises important issues about how health care is allocated, and the use of guidelines in doing so. |
| Accession Number | CPA-970708228 B |
| Classmark | LLD: WEC: L4: QA: 583: 7Y: 7S: 8 |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |